Viekirax Joins Fray in Hep C Market, Can It Crack into Harvoni’s Stronghold?

As AbbVie GK’s Viekirax (ombitasvir + paritaprevir + ritonavir) is to hit the Japanese hepatitis C space soon after its reimbursement listing on November 26, all eyes are now riveted on whether it can cut into archrival Harvoni’s (ledipasvir +...read more